Stephanie Markovina, M.D., Ph.D

Assistant Professor
Radiation Oncology

Cancer Biology Program
Molecular Cell Biology Program

  • 314 747-1786

  • smarkovina@wustl.edu

  • https://markovinalab.wustl.edu/

  • Studies novel metrics to serve dual purpose as biomarkers for prognosis and response to radiation therapy, as well as therapeutic targets for human solid tumors such as cervical and anal cancers.

Research Abstract:

High energy ionizing radiation (IR) is an integral part of cancer therapy for most patients diagnosed with this diverse disease. While IR is effective in killing a large proportion of many tumor cell types, certain cancers are inherently resistant to the effects of IR, and other cancers will respond to IR initially, but eventually regrow, indicating that at least a small population of cancer cells in the original tumor were resistant to high doses of radiation. Understanding the genetic, epigenetic and molecular signaling pathways involved in this cellular resistance is critical to predicting which tumors are likely to be resistant to standard therapy, and also to developing new therapies to use in alone or in conjunction with IR to improve its efficacy and reduce the risk of recurrence.

Much work over the past century has identified critical components for both normal and tumor cell recovery from IR-induced damage. Nevertheless, questions regarding the mechanisms of cell death induced by IR and all of the molecular events sufficient for tumor cell survival remain unanswered. We are taking a multi-faceted approach to better understand factors at play in human tumor radiation resistance and how we can target these defense mechanisms to make tumor cells more susceptible to radiation-induced death.

Selected Publications:

Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. “Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-kB activity and increases drug resistance in multiple myeloma.” J Biol Chem, 2017 Dec 26. pii: jbc.RA117.000667. doi: 10.1074/jbc.RA117.000667. [Epub ahead of print], PMID: 29279332.

Perry Grigsby, M.D., Adnan Elhammali, M.D., Ph.D., Fiona Ruiz, B.S., Stephanie Markovina, M.D., Ph.D, Michael Mclellan, Ph.D., Christopher Miller, Ph.D., Anupama Chundury, M.D., Anh L. Ta, B.S., Ramachandran Rashmi, Ph.D., John D. Pfeifer, M.D., Ph.D., Robert Fulton, Ph.D., Todd DeWees, Ph.D., Julie K. Schwarz, M.D., Ph.D., “Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.” Oncotarget, 2017 Dec 23;9(3):4061-4073.

Stephanie Markovina, Songyan Wang, Lauren Henke MD, Clifford Luke PhD, Stephen Pak PhD, Todd DeWees PhD, John Pfeifer MD/PhD, Julie Schwarz MD/PhD, Xiaowei Wang PhD, David Mutch MD, Matthew Powell MD, Barry Siegel MD, Farrokh Dehdashti MD, Gary Silverman MD/PhD, and Perry Grigsby MD. “Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.” British Journal of Cancer, 2018 Jan;118(1):72-78. doi: 10.1038/bjc.2017.390.

Stephanie Markovina, Marshall Meeks, Shahed Badiyan, Joel Vetter, Hiram Gay, Alethea Paradis, Jeff Michalski, Gurdarshan Sandhu,“Superior Metastasis-Free Survival for Patients with High Risk Prostate Cancer Treated with Definitive Radiation Therapy Compared to Radical Prostatectomy; A Propensity Score Matched Analysis.” In press, Advances in Radiation Oncology, DOI: https://doi.org/10.1016/j.adro.2017.12.001.

Stephanie Markovina, Fady Youssef, Amit Roy, Sonya Aggarwal, Shariq Khwaja, Todd DeWees, Benjamin Tan, Stephen Hunt, Robert Myerson, Daniel Chang, Parag Parikh and Jeffrey Olsen, “Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.” Int J Radiat Oncol Biol Phys. 2017 Oct 1; 99(2):417-426. PMID: 28871992.

Last Updated: 8/22/2018 10:45:50 AM

Back To Top

Follow us: